Recently, investment firm B. Riley downgraded its rating on Centessa Pharmaceuticals plc (stock code: CNTA) from "Buy" to "Neutral".

Meanwhile, the institution raised its target share price from $42 to $45. This rating adjustment reflects analysts' reassessment of the company's current valuation and future development potential. While the increase in target price indicates recognition of long-term value, the downgrade suggests that, in the short term, the share price may have already approached a reasonable range.